Senate Hearing On Ozempic, Wegovy Highlights Concerns About PBMs, International Price Disparities

Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.

 
• By Cathy Kelly
  
Generate a summary of this article
Listen to this article
Beta

Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.

Senate committee chairman Bernie Sanders is trying to persuade Novo Nordisk to commit to reduced list prices for Ozempic and Wegovy in return from commitments from the major PBMs to provide preferential access to the drugs.

Key Takeaways
  • Bernie Sanders wants to broker a deal between PBMs and Novo Nordisk to allow lower priced Wegovy and Ozempic to retain preferential formulary access.

Novo Nordisk President and CEO Lars Jorgensen mostly parried challenges to the company’s US pricing for its mega-blockbusters Ozempic and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pricing Debate

PS-MarketAccess (Premium-2): Why Financial Scammers Are So Successful Targeting Doctors

 
• By Nabil

Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.

Senate Hearing On Ozempic, Wegovy Highlights Concerns About PBMs, International Price Disparities

 
• By Cathy Kelly

Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.

‘Alternative' PBMs Say Vertical Integration Unfairly Carving Them Out Of The Game

 
• By Sarah Karlin-Smith

Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.

US FDA Biologics Designation As Price Protection: Lilly Charts New Course With Retatrutide

 
• By Cathy Kelly

An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.

More from PBMs

PBM Rebating Practices: How Much Do Employer Plan Sponsors Really Know?

 
• By Cathy Kelly

A National Pharmaceutical Council survey of self-insured employers offers a new perspective on pharmacy benefit manager claims that rebating practices only reflect the decisions made by their clients.

Looming Step Therapy Ban In Illinois Is ‘Game Changer,’ Could Start Trend

 
• By Tim Casey

Federal legislation on PBM reforms has stalled, but state efforts remain active. Illinois’ Healthcare Protection Act includes several other limits on insurer power, including prohibiting prior authorization for inpatient mental health care.

Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes

 
• By Michael McCaughan

Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.